{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:26:52Z","timestamp":1790008012389,"version":"4.0.1"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2409,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serum thymidine kinase 1 (sTK1) activity is closely correlated with DNA synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluate sTK1 activity as a biomarker for treatment response and early detection of relapse in dogs with lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Ninety-seven client-owned dogs with naive or relapsed lymphoma and 23 healthy dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective study. Serum TK1 activity measured by refined ELISA-based method (DiviTum assay, Biovica International) before treatment, at clinical response, and every 4\u2009weeks until relapse or last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum TK1 activity was \u226420 Du\/L in 96% (22\/23) of healthy dogs. Pretreatment sTK1 activity was &amp;gt;20 Du\/L in 88% (85\/97) dogs with lymphoma. At clinical response, sTK1 activity was significantly lower in dogs with complete (CR, n\u2009=\u200936) versus partial (PR, n\u2009=\u200929) response (P &amp;lt;\u2009.0001). Sensitivity (Se) and specificity (Sp) of sTK1 activity for detecting nonfully responders were 76% and 100%, respectively, with cutoff of 119.5 Du\/L (AUC, 0.90; 95%-CI, 0.81-0.98; P &amp;lt;\u2009.0001). In dogs with CR, a 5-fold increase in sTK1 activity at a 4-week interval predicted relapse at the subsequent 4-week assessment with a Se 50% and Sp 94% (AUC, 0.72; 95%-CI, 0.55-0.90; P =\u2009.02). An increase of sTK1 activity (&amp;gt;2.7-fold value measured at clinical response) predicted relapse at subsequent 4-week assessment with a Se 61% and Sp 88% (AUC, 0.79; 95%-CI, 0.64-0.95; P =\u2009.004).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Monitoring sTK1 activity could help to detect complete responders and early disease progression in dogs with lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15513","type":"journal-article","created":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T02:55:51Z","timestamp":1558839351000},"page":"1728-1739","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-2842","authenticated-orcid":false,"given":"Pierre","family":"Boy\u00e9","sequence":"first","affiliation":[{"name":"Oncovet Department of Medical Oncology, , Villeneuve d'Ascq,","place":["France"]},{"name":"OCR (Oncovet-Clinical-Research) , Loos,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Floch","sequence":"additional","affiliation":[{"name":"Oncovet Department of Medical Oncology, , Villeneuve d'Ascq,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Serres","sequence":"additional","affiliation":[{"name":"Oncovet Department of Medical Oncology, , Villeneuve d'Ascq,","place":["France"]},{"name":"OCR (Oncovet-Clinical-Research) , Loos,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vyn","family":"Geeraert","sequence":"additional","affiliation":[{"name":"Oncovet Department of Medical Oncology, , Villeneuve d'Ascq,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clerson","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies , Roubaix,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Siomboing","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies , Roubaix,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Bergqvist","sequence":"additional","affiliation":[{"name":"Biovica International AB , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Sack","sequence":"additional","affiliation":[{"name":"Biovica International AB , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Tierny","sequence":"additional","affiliation":[{"name":"Oncovet Department of Medical Oncology, , Villeneuve d'Ascq,","place":["France"]},{"name":"OCR (Oncovet-Clinical-Research) , Loos,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"issue":"4","key":"2026020304350656700_jvim15513-bib-0001","first-page":"403","article-title":"The epidemiology of canine leukemia and lymphoma","author":"Dorn","year":"1970","journal-title":"Bibl Haematol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0002","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1939-1676.2008.0133.x","article-title":"Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy","volume":"22","author":"Merlo","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2017","article-title":"The dog as a possible animal model for human non-Hodgkin lymphoma: a review","volume":"31","author":"Marconato","year":"2013","journal-title":"Hematol Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0004","article-title":"The comparative diagnostic features of canine and human lymphoma","volume":"3","author":"Seelig","year":"2016","journal-title":"Vet Sci"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0005","first-page":"993","article-title":"Epizootiologic characteristics of canine and feline leukemia and lymphoma","volume":"28","author":"Dorn","year":"1967","journal-title":"Am J Vet Res"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0006","first-page":"1179","article-title":"Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology","volume":"22","author":"Teske","year":"1994","journal-title":"Exp Hematol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0007","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1748-5827.2001.tb02485.x","article-title":"Prognostic variables in canine multicentric lymphosarcoma","volume":"42","author":"Dobson","year":"2001","journal-title":"J Small Anim Pract"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1476-5810.2003.00025.x","article-title":"Breed incidence of lymphoma in a UK population of insured dogs","volume":"1","author":"Edwards","year":"2003","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0009","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0010","article-title":"Comparative oncology: what dogs and other species can teach us about humans with cancer","volume":"370","author":"Schiffman","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1993.tb01021.x","article-title":"Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma","volume":"7","author":"Keller","year":"1993","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1939-1676.1998.tb02151.x","article-title":"A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma","volume":"12","author":"Zemann","year":"1998","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0013","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1939-1676.2000.tb02224.x","article-title":"Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"14","author":"Chun","year":"2000","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0014","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1939-1676.2006.tb01810.x","article-title":"Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol","volume":"20","author":"Simon","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0015","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1939-1676.2007.tb01959.x","article-title":"Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma","volume":"21","author":"Hosoya","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0016","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1939-1676.2007.tb01960.x","article-title":"Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma","volume":"21","author":"Rassnick","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0017","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2460\/javma.232.6.879","article-title":"Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma","volume":"232","author":"Simon","year":"2008","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0018","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1476-5829.2010.00224.x","article-title":"Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs","volume":"8","author":"Rassnick","year":"2010","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0019","first-page":"196","article-title":"Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases","volume":"8","author":"Sorenmo","year":"2010","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2460\/javma.238.4.501","article-title":"Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007)","volume":"238","author":"Flory","year":"2011","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0021","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1476-5829.2012.00324.x","article-title":"Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma","volume":"11","author":"Burton","year":"2013","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1476-5829.2011.00311.x","article-title":"Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma","volume":"11","author":"Elliott","year":"2013","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0023","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/vco.12163","article-title":"Retrospective analysis for treatment of na\u00efve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol","volume":"14","author":"Curran","year":"2016","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0024","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2460\/javma.1994.205.12.1722","article-title":"Prognostic factors for treatment of malignant lymphoma in dogs","volume":"205","author":"Teske","year":"1994","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/vco.12244","article-title":"Conformity and controversies in the diagnosis, staging and follow-up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature","volume":"15","author":"Marconato","year":"2017","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0026","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1439-0442.2002.00458.x","article-title":"A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000)","volume":"49","author":"Jagielski","year":"2002","journal-title":"J Vet Med A Physiol Pathol Clin Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0027","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2460\/javma.237.9.1052","article-title":"Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)","volume":"237","author":"Beaver","year":"2010","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0028","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1476-5829.2010.00230.x","article-title":"CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma","volume":"9","author":"Rebhun","year":"2011","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0029","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2460\/javma.238.4.480","article-title":"Predictors of long-term survival in dogs with high-grade multicentric lymphoma","volume":"238","author":"Marconato","year":"2011","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1939-1676.2008.0041.x","article-title":"Canine lymphoproliferative disease characterized by lymphocytosis: immunophenotypic markers of prognosis","volume":"22","author":"Williams","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0031","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1476-5829.2011.00317.x","article-title":"Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma","volume":"11","author":"Flood-Knapik","year":"2013","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0032","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tvjl.2003.10.009","article-title":"Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy","volume":"167","author":"Ponce","year":"2004","journal-title":"Vet J"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0033","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/0300985813478210","article-title":"Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival","volume":"50","author":"Valli","year":"2013","journal-title":"Vet Pathol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0034","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1939-1676.2006.tb02833.x","article-title":"CCNU in the treatment of canine epitheliotropic lymphoma","volume":"20","author":"Williams","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1939-1676.2008.0270.x","article-title":"Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs","volume":"23","author":"Rassnick","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0036","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0300985812451625","article-title":"Hepatosplenic and hepatocytotropic T-cell lymphoma: two distinct types of T-cell lymphoma in dogs","volume":"50","author":"Keller","year":"2013","journal-title":"Vet Pathol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1476-5829.2003.00009.x","article-title":"Dexamethasone treatment of a canine, but not human, tumour cell line increases chemoresistance independent of P-glycoprotein and multidrug resistance-related protein expression","volume":"1","author":"Mealey","year":"2003","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0038","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1939-165X.1997.tb00711.x","article-title":"Application of rapid CD3 immunophenotype analysis and argyrophilic nucleolar organizer region (AgNOR) frequency to fine needle aspirate specimens from dogs with lymphoma","volume":"26","author":"Vail","year":"1997","journal-title":"Vet Clin Pathol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0039","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1476-5829.2006.00103.x","article-title":"Telomerase activity and telomerase reverse transcriptase catalytic subunit expression in canine lymphoma: correlation with Ki67 immunoreactivity","volume":"4","author":"Renwick","year":"2006","journal-title":"Vet Comp Oncol"},{"key":"2026020304350656700_jvim15513-bib-0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1023\/B:VERC.0000014201.82393.67","article-title":"Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) and LDH isoenzymes in canine lymphoma","volume":"27 Suppl 1","author":"Zanatta","year":"2003","journal-title":"Vet Res Commun"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0041","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2460\/javma.236.9.969","article-title":"Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma","volume":"236","author":"Marconato","year":"2010","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0042","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1016\/S0021-9258(18)68484-4","article-title":"Regulation of human thymidine kinase during the cell cycle","volume":"263","author":"Sherley","year":"1988","journal-title":"J Biol Chem"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0043","first-page":"2538","article-title":"Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis","volume":"11","author":"Kauffman","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0044","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00018-002-8511-x","article-title":"Structure and function of cellular deoxyribonucleoside kinases","volume":"59","author":"Eriksson","year":"2002","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2010.00238.x","article-title":"Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases","volume":"9","author":"Von Euler","year":"2011","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0046","doi-asserted-by":"crossref","first-page":"17970","DOI":"10.1073\/pnas.0406332102","article-title":"Structures of thymidine kinase 1 of human and mycoplasmic origin","volume":"101","author":"Welin","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0047","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/MCB.24.2.514-526.2004","article-title":"Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex\/cyclosome-CDH1-mediated pathway","volume":"24","author":"Ke","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0048","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/cbr.1993.8.189","article-title":"Thymidine kinases: the enzymes and their clinical usefulness","volume":"8","author":"Hannigan","year":"1993","journal-title":"Cancer Biother"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0049","first-page":"505","article-title":"Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity\u2014evaluation of a new, fully automated non-radiometric assay","volume":"34","author":"Von Euler","year":"2009","journal-title":"Int J Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01715117","article-title":"Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications","volume":"65","author":"Hallek","year":"1992","journal-title":"Ann Hematol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0051","first-page":"1732","article-title":"Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia","volume":"93","author":"Hallek","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0052","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1586\/14737159.1.4.428","article-title":"Thymidine kinase: diagnostic and prognostic potential","volume":"1","author":"O'Neill","year":"2001","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0053","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1939-1676.2004.tb02608.x","article-title":"Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease","volume":"18","author":"Von Euler","year":"2004","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0054","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1292\/jvms.59.957","article-title":"Plasma thymidine kinase activity in dogs with lymphoma and leukemia","volume":"59","author":"Nakamura","year":"1997","journal-title":"J Vet Med Sci"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2011.00296.x","article-title":"Thymidine kinase assay in canine lymphoma","volume":"11","author":"Elliott","year":"2013","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0056","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Veterinary cooperative oncology group. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a veterinary cooperative oncology group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0057","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tvjl.2013.05.003","article-title":"Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: prognostic significance and proposal of a cut-off value","volume":"197","author":"Marconato","year":"2013","journal-title":"Vet J"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0058","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0021-9975(97)80065-5","article-title":"Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas","volume":"117","author":"Fournel-Fleury","year":"1997","journal-title":"J Comp Pathol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0059","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10549-013-2579-x","article-title":"Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial","volume":"139","author":"Bj\u00f6hle","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1515\/cclm-2012-0162","article-title":"Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients","volume":"51","author":"Nisman","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0061","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5507\/bp.2014.008","article-title":"Analysis of thymidine kinase serum levels by novel method DiviTum in multiple myeloma and monoclonal gammopathy of undetermined significance\u2014comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET\/CT","volume":"159","author":"Bacovsky","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0062","first-page":"1321","article-title":"Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia","volume":"70","author":"Stelmach","year":"2016","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0063","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-017-0913-7","article-title":"Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib","volume":"19","author":"Bagegni","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0064","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0000000000000966","article-title":"Preoperative serum thymidine kinase activity as novel monitoring, prognostic, and predictive biomarker in pancreatic cancer","volume":"47","author":"Felix","year":"2018","journal-title":"Pancreas"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0065","article-title":"Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma","volume":"12","author":"Boy\u00e9","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0066","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-14-3174","article-title":"Phase I clinical pharmacology study of F14512, a new polyamine-Vectorized anticancer drug, in naturally occurring canine lymphoma","volume":"21","author":"Tierny","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0067","first-page":"691","article-title":"Thymidine kinase isoenzymes in human malignant lymphoma","volume":"41","author":"Ellims","year":"1981","journal-title":"Cancer Res"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0068","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/bjc.1983.78","article-title":"The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma","volume":"47","author":"Gronowitz","year":"1983","journal-title":"Br J Cancer"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0069","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/bjc.1995.213","article-title":"Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas","volume":"71","author":"Rehn","year":"1995","journal-title":"Br J Cancer"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2141.1995.tb03386.x","article-title":"Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia","volume":"90","author":"Sadamori","year":"1995","journal-title":"Br J Haematol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0071","first-page":"3025","article-title":"Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma","volume":"17","author":"Poley","year":"1997","journal-title":"Anticancer Res"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0072","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.rvsc.2005.05.001","article-title":"A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs","volume":"80","author":"Von Euler","year":"2006","journal-title":"Res Vet Sci"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0073","article-title":"A new Sandwich ELISA for quantification of thymidine kinase 1 protein levels in sera from dogs with different malignancies can aid in disease management","volume":"10","author":"Jagarlamudi","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0074","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/vco.12112","article-title":"Immunophenotypic characterization of canine malignant lymphoma: a retrospective study of cases diagnosed in Poland lower Silesia, over the period 2011-2013","volume":"14","author":"Pawlak","year":"2016","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/vco.12052","article-title":"Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease","volume":"13","author":"Selting","year":"2015","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0076","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1373\/clinchem.2003.030379","article-title":"Sensitive nonradiometric method for determining thymidine kinase 1 activity","volume":"50","author":"Ohrvik","year":"2004","journal-title":"Clin Chem"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0077","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/CBM-2010-0148","article-title":"Serum thymidine kinase 1 activity in breast cancer","volume":"7","author":"Nisman","year":"2010","journal-title":"Cancer Biomark"},{"issue":"4","key":"2026020304350656700_jvim15513-bib-0078","doi-asserted-by":"crossref","first-page":"513.e1","DOI":"10.1016\/j.urology.2010.04.034","article-title":"Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy","volume":"76","author":"Nisman","year":"2010","journal-title":"Urology"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15513","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/4\/1728\/66657956\/jvim15513.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/4\/1728\/66657956\/jvim15513.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:35:58Z","timestamp":1770111358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/33\/4\/1728\/8447895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15513","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"2018-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}